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Abstract
Human clinical trials in type 1 diabetes (T1D) patients using mesenchymal stem cells (MSC) are
presently underway without prior validation in a mouse model for the disease. In response to this
void, we characterized bone marrow-derived murine MSC for their ability to modulate immune
responses in the context of T1D, as represented in NOD mice. In comparison to NOD mice,
BALB/ c-MSC mice were found to express higher levels of the negative costimulatory molecule
PD-L1 and to promote a shift toward Th2-like responses in treated NOD mice. In addition,
transfer of MSC from resistant strains (i.e., nonobese resistant mice or BALB/c), but not from
NOD mice, delayed the onset of diabetes when administered to prediabetic NOD mice. The
number of BALB/c-MSC trafficking to the pancreatic lymph nodes of NOD mice was higher than
in NOD mice provided autologous NOD-MSC. Administration of BALB/c-MSC temporarily
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resulted in reversal of hyperglycemia in 90% of NOD mice (p = 0.002). Transfer of autologous
NOD-MSC imparted no such therapeutic benefit. We also noted soft tissue and visceral tumors in
NOD-MSC-treated mice, which were uniquely observed in this setting (i.e., no tumors were
present with BALB/c- or nonobese resistant mice-MSC transfer). The importance of this
observation remains to be explored in humans, as inbred mice such as NOD may be more
susceptible to tumor formation. These data provide important preclinical data supporting the basis
for further development of allogeneic MSC-based therapies for T1D and, potentially, for other
autoimmune disorders.
Mesenchymal stem cells (MSC)4 are multipotent progenitor cells that can be isolated from a
number of sources, including bone marrow (BM). MSC have been noted for their ability to
give rise to cells of various lineages, including bone, cartilage, and adipose tissues (1).
Isolation of MSC is commonly performed from BM, based on procedures involving the
adherence of fibroblast-like cells to the plastic substrate of cell culture plates, together with
the exclusion of marrow-derived hematopoietic cells (2, 3). MSC have been characterized in
humans and several animal models using a battery of negative and positive cellular markers
(3). Although subject to some discrepancy, a consensus opinion suggests they lack specific
cell surface markers of hematopoietic cells (CD34), monocytes/macrophages (CD14),
lymphocytes (CD11a/LFA-1), leukocytes (CD45), RBC (glycophorin A), and endothelial
cells (CD31), but express SH2 (CD105 or endoglin), SH3, SH4, CD44, and CD29 (3–6).
The primary impetus behind MSC research has been their developmental plasticity and
ability to replace injured tissues, yet MSC have also been noted for their profound
immunomodulatory effects in vivo (7, 8). Indeed, MSC have been used to reduce the burden
of a variety of immune-mediated diseases, including graft rejection, graft-vs-host disease,
collagen-induced arthritis, and myelin oligodendrocyte glycoprotein-induced experimental
autoimmune encephalomyelitis (8–11). A significant number of trials have also been
designed to assess the safety, feasibility, and efficacy of MSC therapy for a multitude of
disorders in humans (12–14). Among these, Le Blanc et al. have shown promising results in
using MSC for the treatment of steroid-refractory graft-vs-host disease in humans (15, 16).
Clinical studies have also yielded success in treating common diseases such as cancer, heart
failure from massive myocardial infarction, and neurological diseases (17–23). Taken
collectively, these reports indicate that MSC may be of considerable therapeutic benefit and
provide a basis for the development of efficacious and safe stem cell therapies (24). At least
two clinical trials using allogeneic (Osiris) and autologous (European Consortium) MSC for
therapy of recent onset type 1 diabetes (T1D) have recently been formed, without preclinical
data (14). In this report, we characterize MSC obtained from diabetes-prone as well as -
resistant mice, and evaluate their immunomodulatory effects in autoimmune T1D by
assessing their ability to prevent the onset of diabetes, or to reverse overt hyperglycemia, in
NOD mice.
Materials and Methods
Mice
BALB/c ByJ, NOD/LtJ, nonobese resistant mice (NOR)/LtJ, BDC2.5, CBA/J, and C57BL/6
mice were purchased from The Jackson Laboratory. Animals were cared for and/or bred
under specific pathogen-free conditions at the Harvard Medical School Facilities for Animal
Care and Housing. Protocols were approved by the Institutional Animal Care and Use
Committee.
4Abbreviations used in this paper: MSC, mesenchymal stem cells; BM, bone marrow; DC, dendritic cell; NOR, nonobese resistant;
P4, passage 4; PLN, pancreatic lymph node; T1D, type 1 diabetes; Treg, T regulatory cell.
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MSC culture
To generate MSC, BM mononuclear cells were isolated from the femurs and tibiae of at
least five mice to minimize cell variability. Cells were seeded in flasks at a concentration of
10 × 106/25 cm2 in M10 medium (DMEM medium [Cambrex] containing 10% FCS
[HyClone], 1% penicillin-streptomycin, and 1% L-glutamine [both from Cambrex]). To
examine MSC in an inflammatory setting, 7.5 × 105 NOD- or BALB/c-MSC/well were
cultured for 48 h in 6-well plates in M10 medium containing 10 ng/ml recombinant murine
IL-1β (PeproTech).
Flow cytometric analysis
MSC were analyzed for surface expression of a battery of markers at passage 4 (P4). Anti-
mouse Abs against CD45, Sca-1, CD44, CD90.2, CD73, CD80, CD86, CD40, CD40L, Fas,
and FasL were purchased from BD Biosciences. Abs purchased from eBioscience were
CD105, CD29, ICOS, OX40, PD-1, PD-L1, and PD-L2. T regulatory cells (Tregs) were
assessed using CD4, CD25, and FoxP3 (eBioscience).
MSC differentiation
To ensure that our cultured cells had multipotent potential, we tested MSC P4 cultures for
their ability to undergo differentiation into chondrocytes, osteocytes, and adipocytes as
previously published (10). Chondrogenic differentiation was induced by 50 µg/ml ascorbic
acid and 1 ng/ml TGFβ-1 (PeproTech); osteogenic differentiation was induced by 50 µg/ml
ascorbic acid, 10 mM sodium α-glycerophosphate, and 10−8 M dexamethasone; adipogenic
differentiation was induced by 10−7 M dexamethasone and 6 ng/ml insulin.
Immunohistochemistry and electron microscopy
Following fixation of adherent BALB/c- and NOD-MSC on slides using Merkofix (EMD
Chemicals), MSC were incubated with primary Ab at 4°C overnight followed by the avidin-
biotin complex procedure (25). Immunoreactions were employed using CD34, CD44, and
CD105 (eBioscience) and Fas (Santa Cruz Biotechnology) abs. For electron microscopy,
samples were fixed for 2 h in a solution of 2% paraformaldehyde and 2% glutar-aldehyde in
0.05 M pH 7.3 cacodylate buffer at 4°C
Islet pathology and immunohistochemistry
Immunohistology was performed as described previously (26).
Autoreactive T cell proliferation
T cells were extracted from spleens of BDC2.5 mice with CD4 magnetic beads (Miltenyi
Biotec). Cells were then labeled using the Vybrant CFDA SE Cell Tracer kit (Invitrogen).
Irradiated dendritic cells (DC; 5 × 104) from NOD mice were incubated with 1 × 105 CFSE-
labeled CD4+ BDC2.5 cells and 100 ng/ml BDC2.5 islet peptide as previously described
(26). BALB/c- and NOD-MSC (2 × 104) irradiated with 3000 rad were added to assess the
immunomodulatory effect on proliferation compared with control wells. At 72 h, cells were
subjected to flow cytometric analysis to assess CFSE dilution.
Allogeneic MLR
DC (5 × 104) generated from C57BL/6 BM were harvested at day 8 and used to stimulate 1
× 105 CD4+ BALB/c cells isolated using CD4 microbeads (Miltenyi Biotec). Irradiated
BALB/c- and NOD-MSC (2 × 104) were added to determine their effect on T cell
proliferation, in which cell counts were measured at day 3 following pulsing for 3 h with
TdR (PerkinElmer) with a liquid scintillation counter.
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ELISPOT
The effect of MSC on cytokine production of autoreactive T cells was examined with the
ELISPOT assay using 1 × 105 CD4+ BDC2.5 cells, 5 × 104 irradiated NOD DC, and 100 ng/
ml BDC2.5 islet peptide for in vitro studies and 1 × 106 splenocytes with 100 µg/ml BDC2.5
islet peptide for ex vivo prevention studies to assess IFN-γ, IL-4, IL-6, and IL-10 as
described previously (26).
Luminex assay
To assess cytokine production of murine serum and culture supernatant samples, a 21-plex
cytokine kit (Millipore) was used according to the manufacturer’s instructions to analyze
production of indicated cytokines.
Prevention and reversal studies
To determine the effect of MSC administration on the prevention of diabetes, we injected 5
× 105 MSC (BALB/c or NOD) i.v. once a week for 4 wk in NOD mice beginning at 10 wk
of age. Blood glucose measurements were performed by tail bleeding according to National
Institutes of Health guidelines. For prevention studies, >250 mg glucose/dL for more than 3
days was indicative of greater than 80% loss of islet mass and onset of diabetes. For reversal
studies, we placed a s.c. sustained-release insulin pellet (LinBit; LinShin Canada) on day 2
of hyperglycemia. Within 24 h of pellet placement, we performed the first MSC injection (1
× 106 cells i.v.). After all treatments, mice were monitored daily by blood glucose
measurement until the time of sacrifice.
Gene array
RNA was isolated from MSC at P4 with the RNeasy kit (Qiagen) and was analyzed as
previously described (26).
Trafficking studies
BALB/c- and NOD-MSC were harvested and labeled with CFSE as above. Cells were then
injected into the tail vein of 10-wk-old female NOD mice. Age-matched, untreated NOD
female mice were used to establish basal tissue autofluorescence. Animals were killed at day
3 postinjection. Spleen, pancreatic lymph nodes (PLN), and pancreata were removed, frozen
in OCT and cut; 4-µm sections of the samples were examined to discern CFSE-labeled cells.
Results
MSC morphology and differentiation
To characterize our MSC colonies, MSC were generated from BM harvested from 10-wk-
old female NOD and BALB/c mice and were evaluated morphologically by light and
electron microscopy. Although BALB/c-MSC displayed a typical small spindle fibroblast-
like pattern with eosinophilic cytoplasm and large clear nuclei showing dispersed chromatin
and evident nucleoli, NOD-MSC formed large aggregates, primarily composed of packed,
mid-sized to large cells, with rare spindle fibroblast-like cells (Fig. 1A). At the
ultrastructural level, BALB/c-MSC showed more abundant cytoplasm with rare short
microvilli compared with NOD-MSC (Fig. 1, E and F). By immunohistochemistry, both
BALB/c- and NOD-MSC were observed to be negative for CD34 (Fig. 1B) and positive for
CD44 (Fig. 1C) and CD105 (Fig. 1D), an expression pattern reported to identify MSC (14,
24). MSC cultured from NOD and BALB/c mice were able to differentiate into
chondrocytes, osteocytes, and adipocytes (Fig. 1, G–I).
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MSC flow cytometric characterization
We also evaluated the expression of stem cell and immunoregulatory markers by flow
cytometry. NOD- and BALB/c-MSC were characterized at P4 with the following panel of
Abs: 1) stem cell markers (CD29, CD44, CD73, CD105, CD166, and Sca-1); 2)
hematopoietic/lineage markers (CD45 and CD90.2); 3) costimulatory molecules (positive:
CD40, CD80, CD86, and OX40; negative: PD-1, PD-L1, and PD-L2); and 4) apoptotic
factors (Fas and FasL). Stem cell marker expression was positive for CD29, CD44, CD73,
CD105, CD166, and Sca-1 in both strains (Fig. 2, A, B, D, F, G, and H, respectively),
although CD105 expression was lesser in NOD- than in BALB/c-MSC (p = 0.001; Fig. 2F).
Neither BALB/c- nor NOD-MSC expressed lymphoid or myeloid markers (CD45 and
CD90.2; Fig. 2, C and E). Positive costimulatory molecules appeared to be negative in both
strains (Fig. 2, I–L), and the negative costimulatory molecules PD-1 and PD-L2 were not
expressed in either strain (Fig. 2, M and O). However, PD-L1 expression was found to be 4-
fold greater in BALB/c-MSC compared with NOD-MSC (p = 0.01; Fig. 2N). Although FasL
was negative in both NOD- and BALB/c-MSC mice (Fig. 2Q), Fas (a receptor with
proapoptotic properties) is expressed by both strains (Fig. 2P). We and others have
previously shown that diabetes development is accelerated in NOD mice by treatment with a
blocking PD-L1 Ab, as well as in PD-L1-deficient NOD mice (27, 28). Furthermore,
Augello et al. demonstrated that MSC regulate the immune response in vitro through cell-to-
cell contact, which appears to be largely dependent on the PD-1 pathway (29). We therefore
further investigated the dynamic changes that occur in the expression of PD-L1 following
MSC stimulation with IL-1β, thereby mimicking an in vivo inflammatory setting relative to
T1D and based on the notion that the immunoregulatory characteristics of MSC most likely
change in an inflammatory environment. Following challenge with IL-1β for 48 h, the
difference in the expression of PD-L1 became more distinct in BALB/c-MSC (BALB/c =
21.0 ± 4.4 vs NOD = 5.4 ± 1.0%, p = 0.024; Fig. 2R). Altogether, a greater level of PD-L1
on BALB/c-MSC vs NOD-MSC may enable BALB/c-MSC to deliver immunosuppressive
signals and to maintain quiescence of autoreactive T cells.
Cytokine profile of BALB/c- vs NOD-MSC and their immunosuppressive capabilities in
alloimmune and autoimmune settings
To elucidate the regulatory function of MSC, we evaluated their production of inflammatory
cytokines that may play a role in the pathogenesis of T1D, using the Luminex assay to
analyze the supernatants of BALB/c- and NOD-MSC cultures at P4. Interestingly, NOD-
MSC appeared to produce more proinflammatory cytokines and chemokines, including
IL-1α (p = 0.01), IL-1β (p = 0.04), IP-10 (p = 0.003), and MCP-1 (p = 0.007) (Fig. 3A) than
BALB/C-MSC did. No difference was noted in the levels of IFN-γ, IL-6, IL-9, IL-10,
IL-12p40, IL-12p70, IL-15, MIG, or RANTES production. The immunosuppressive abilities
of BALB/c- and NOD-MSC were also studied in an MLR assay. BALB/c- or NOD-MSC (2
× 104) were added, following irradiation with 3000 rad to prevent their proliferation in
culture, to a fully mismatched MLR assay in which 1 × 105 C57BL/6 CD4+ cells isolated
from splenocytes were used as responders, with irradiated DC generated from CBA BM
used as stimulators. MSC were therefore added as third-party cells. BALB/c- and NOD-
MSC were both found to inhibit the MLR response in comparison to controls (p < 0.001),
although BALB/c-MSC were noted to be more immunosuppressive (p < 0.001) in
comparison to NOD-MSC (Fig. 3B). These findings confirm that both strains have similar
immunosuppressive properties in an alloimmune setting in vitro. To evaluate the
immunomodulatory abilities of MSC in an autoimmune setting in vitro, we used an
autoreactive T cell proliferation assay shown to provide useful information with respect to T
cell immunity to islet-cell Ags in T1D (26). The immunosuppressive properties of MSC
were thus examined by assessing their effect on the proliferation of autoreactive T cells
extracted from transgenic TCR BDC2.5 mice in response to autoantigen by CFSE dilution.
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CFSE-labeled CD4+ T cells purified from splenocytes of BDC2.5 mice were cultured for 3
days in the presence of BM-derived NOD DC, BALB/c- or NOD-MSC, and 100 ng/ml
BDC2.5 peptide. As shown in Fig. 3C, both BALB/c- and NOD-MSC comparably inhibited
the proliferative response of CD4+ T cells (p = 0.04 compared with untreated control),
demonstrating that both strains of MSC have similar immunomodulatory properties against
autoreactive T cells in vitro.
Prevention of autoimmune diabetes in prediabetic NOD mice
We next tested the ability of P4 NOD- or BALB/c-MSC to prevent diabetes onset when
injected into prediabetic NOD mice. Specifically, we injected 5 × 105 BALB/c- or NOD-
MSC i.v. once a week for 4 wk into prediabetic 10-wk-old NOD mice (n = 35 for BALB/c-
MSC, n = 29 for NOD-MSC, n = 29 for controls, n = 3 experiments). As shown in Fig. 4A,
BALB/c-MSC (p = 0.04 compared with controls), but not NOD-MSC, significantly delayed
the onset of T1D in 37% of treated NOD mice in the long-term (up to 40 wk of age) as
compared with 20% of control NOD mice. In conjunction with the survival data, we also
assessed the pathological finding of pancreatic islets in treated and control animals.
Pancreatic islet morphology and infiltration were evaluated in MSC-treated or untreated
NOD mice. Pancreata were harvested from normoglycemic NOD mice from the three
groups (BALB/c-MSC-treated, NOD-MSC-treated, and untreated) at three different time
points and were analyzed for infiltration and morphology (n = 3 mice/group). At 14 wk of
age, islets appeared well-preserved in normoglycemic BALB/c-MSC-treated mice, while in
normoglycemic NOD-MSC-treated or in untreated mice, a slightly more pronounced islet
infiltration was observed (data not shown). At 22 wk of age, normoglycemic BALB/c-MSC-
treated mice showed a scanty infiltrate, reduced in quantity to age-matched normoglycemic
NOD-MSC-treated or untreated control mice (Fig. 4B, 1–3, respectively). With respect to
insulitis score, while BALB/c-MSC-treated mice showed a pattern similar to untreated 10-
wk-old normoglycemic NOD mice, the insulitis score of BALB/c-MSC-treated mice was
lower than that of age-matched NOD-MSC-treated and untreated NOD mice (Fig. 4C).
Further investigation of the cell infiltrate subsets revealed fewer CD3+ (Fig. 4B, 4–6) and
B220+ cells (Fig. 4B, 10–12) in BALB/c-MSC-treated mice compared with NOD-MSC-
treated and untreated control mice. Very few FoxP3+ cells were detected within the islets of
all three groups of mice (Fig. 4B, 7–9). Insulin (Fig. 4B, 13–15) and glucagon (Fig. 4B, 16–
18) staining showed well-preserved islets, particularly in the BALB/c-MSC-treated group,
whereas a loss of insulin staining and of islet morphology was evident in NOD-MSC-treated
and untreated control mice. At 40 wk of age, normoglycemic BALB/c-MSC-treated mice
maintained less infiltrated islets than NOD-MSC-treated and untreated control mice (data
not shown). However, insulin staining appeared weak in BALB/c-MSC-treated mice and
was negative in NOD-MSC-treated and untreated control mice, whereas glucagon was
preserved in BALB/c-MSC-treated mice only (data not shown). Altogether, our data support
the fact that BALB/c-MSC are capable of de-laying the onset of diabetes. These are vital
preclinical data to support the concept of translating MSC-based cell therapy to individuals
with T1D.
Evaluation of Th1 vs Th2 cytokine profile and measurement of Tregs following MSC
treatment
The Th1 vs Th2 cytokine shift has also been reported to affect the incidence of T1D (30).
We assessed the Th1/Th2 cytokine patterns in response to MSC treatment by stimulating
splenocytes recovered with BDC2.5 peptide from control and treated animals, as previously
described (26). Splenocytes of normoglycemic BALB/c- or NOD-MSC-treated and
normoglycemic untreated control mice from our prevention studies were isolated at 14 wk of
age (i.e., after 4 wk of treatment) and were challenged with BDC2.5 peptide in an ELISPOT
assay to evaluate IFN-γ, IL-4, and IL-10 production. As shown in Fig. 4D, both BALB/c-
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and NOD-MSC-treated animals exhibited a lower frequency of IFN-γ-producing cells than
untreated normoglycemic NOD mice (p = 0.01 and p = 0.005 respectively for BALB/c- and
NOD-MSC-treated mice). However, a shift toward a Th2 profile, with an increase in
production of IL-4 (p < 0.0001 compared with controls) and IL-10 (p = 0.01 compared with
controls), was evident in splenocytes isolated from BALB/c-MSC-treated mice. Such a shift
was not observed in NOD-MSC-treated mice compared with control during autoantigen
stimulation (Fig. 4D). Th2 cytokines have commonly been reported to confer protection
against Th1-mediated destruction of β-islet cells (31).
Tregs have been shown to play a crucial role in regulating autoimmunity, (32, 33) and MSC
have been shown to facilitate the generation of Tregs (34, 35). Upon examination of the
effect of MSC treatment on Treg percentage, we noted a marginal but not substantial
increase in the percentage of CD4+CD25+FoxP3+ cells at 14 wk of age in the PLN of
normoglycemic BALB/c-MSC-treated, but not of NOD-MSC-treated mice, compared with
untreated age-matched controls (BALB/c-MSC-treated = 12.6 ± 0.8, untreated control =
10.0 ± 0.8, NOD-MSC-treated = 10.3 ± 1.1%, p = 0.04 BALB/c vs NOD-MSC-treated). No
difference was observed in the percentage of Tregs recovered from the spleens of these mice
(data not shown).
Reversal of hyperglycemia in newly hyperglycemic NOD mice
Given the protective effect of BALB/c-MSC observed in our prevention studies, we also
evaluated the ability of BALB/c-MSC to reverse diabetes in new-onset hyperglycemic NOD
mice. After a second consecutive hyperglycemic measurement (>250 mg/dl) within 24 h,
NOD mice were injected i.v. with 1 × 106 BALB/c-MSC twice a week for 4 wk. An insulin
pellet was placed under the skin of the dorsum of hyperglycemic NOD mice to improve
glucose homeostasis. Although control NOD mice invariably returned to hyperglycemia
(mean survival time = 22.5 days; Fig. 5, B and C), seven of eight BALB/c-MSC-treated
mice remained normoglycemic for an average of 41.5 days (p = 0.0002 vs untreated mice;
Fig. 5, A and C). Two BALB/c-MSC-treated mice remained normoglycemic for more than
60 days; one then reverted to hyperglycemia and the other died normoglycemic of unknown
causes (Fig. 5, A and C). Despite the lack of therapeutic efficacy in our prevention studies
using NOD-MSC, we tested the effect of NOD-MSC in reversing NOD mice with recent
onset diabetes. In the three mice treated with NOD-MSC, none experienced reversal of their
diabetes (Fig. 5B). Moreover, we observed tumor formation in all three hosts at the site of
injection in the tail as well as at the site of the resident insulin pellet.
After 14 days of hyperglycemia in untreated NOD mice, islets are extensively infiltrated by
lymphoid cells (Fig. 5D) with disrupted structure and a reduction in insulin and glucagon
staining (data not shown). The lymphoid infiltrate was composed predominantly of B220+
cells, along with a smaller population of CD3 + cells (Fig. 5D) and very few FoxP3+ cells
(data not shown). In the BALB/c-MSC-treated mice 14 days after treatment, islets showed
very mild infiltrates confined to the borders of β cells, with an almost complete absence of
B220+ and CD3+ cells (Fig. 5E), along with well-maintained glucagon staining and scarce
insulin staining (data not shown). More infiltrating cells also appeared to be FoxP3+ cells in
islets of the BALB/c-MSC-treated mice, which were absent in control mice (data not
shown). In the long-term normoglycemic (i.e., 90 days after treatment) BALB/c-MSC-
treated mice, islets still appeared preserved, despite a marked increase in infiltrate (B220+
and CD3+ cells) (Fig. 5F).
Occurrence of neoplasm in autologous MSC-treated mice
A paramount observation noted during our prevention and reversal studies was the
identification of tumors in mice treated with autologous MSC. In prevention and reversal
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groups, NOD mice treated with NOD-MSC developed neoplasia (∼20% and 100%,
respectively), a finding not observed in the BALB/c-MSC-treated group. Most tumors
detected formed nodular masses in the legs and tails of mice (Fig. 6A). Tumors were also
identified as numerous nodules of 0.1 to 0.3 cm in diameter in the lungs and liver of animals
(Fig. 6, B and C). Optical microscopy revealed that the malignant tumor was made up of a
homogeneous population of malignant spindle cells in sheets and fascicles (Fig. 6D). The
tumor was shown to invade muscle, nerve, skin, bone (Fig. 6E), and peritoneum, and was
located adjacent to the colon (Fig. 6F). In the lung, the tumor formed nodular masses with
alveolar wall infiltration (Fig. 6G), and in the liver appeared as nodular masses (Fig. 6H).
The tumor lacked malignant or benign-looking epithelium. Electron microscopy of the
hepatic tumor identified compact, intertwined processes covered by basal lamina, consistent
with Schwann cell differentiation (Fig. 6I). The diagnosis was compatible with a malignant
peripheral nerve sheath tumor. Of note, following injection of BALB/c mice with BALB/c-
MSC, no neoplasia was observed up to 5 wk after the initiation of treatment.
Transcriptome analysis of NOD- and BALB/c-MSC
Following culture and expansion of MSC (as above), mRNA was extracted from MSC for
use in gene expression profile analysis using microarray technology. We examined the gene
expression profile of NOD-MSC (samples no. 1 to 4) and BALB/c-MSC (samples no. 5 to
8) obtained from normoglycemic NOD mice and age-matched BALB/c mice. A striking
differential expression in the pattern of gene regulation across the entire screen was
observed when BALB/c-MSC genes were compared with the NOD-MSC (Fig. 6J). Notably,
a considerable number of genes promoting cell cycle and proliferation were up-regulated in
NOD-MSC (e.g., Plf2, Birc5, Ifgbp3, Sgol2, Btc, and Ccnb1); among these, Plf, Gfra1, and
Ngef are related to neural tumor development, which is consistent with the pathogenesis
behind the formation of neural tumors in our animals (Tables I and II, accession number
GSE15516, http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc = GSE15516). Although the
formation of tumors when using NOD-MSC could be due to an abnormality within the NOD
strain similar to other genetic malformations reported in this strain, the data should raise
awareness regarding the potential tumor formation in settings of autologous MSC in certain
immune disorders (e.g., T1D).
Monitoring MSC trafficking following injection into NOD mice
MSC are able to selectively migrate into sites of injury (36). Furthermore, it has been shown
that diabetogenic T cells are resident to the PLN, where T cells are introduced to β-cell
autoantigens, giving rise to autoantigen-specific T cells (37). To study MSC trafficking in
our experimental settings, BALB/c- as well as NOD-MSC were labeled with CFSE and
were injected into the tail vein of 10-wk-old NOD mice. Pancreata, spleens, and PLN of
treated and untreated animals were harvested at day 3 postinjection. As shown in Fig. 6, the
frequency of trafficked cells was similar in both spleen and pancreas between BALB/ c-
MSC-treated (Fig. 6, L and O, respectively) and NOD-MSC-treated mice (Fig. 6, M and P,
respectively); however, a significant increase in the number of trafficked BALB/c-MSC was
observed in the PLN as compared with NOD-MSC (Fig. 6, R and S, respectively). These
data indicate that the prevention of diabetes observed with treatment of BALB/c-MSC could
be due in part to the preferential trafficking of BALB/c-MSC to the PLN, where they may
interfere or deliver inhibitory signals to prevent the expansion of autoreactive T cells.
Chemokines have increasingly become recognized as the key regulators of such preferential
migration of cells, including MSC (38). It is likely that the disparity in the migration of
MSC from these two strains could be due to the differential expression of chemokine
receptors. We therefore assessed the expression of chemokine receptors CCR5, CCR7,
CXCR3, and CXCR4 on MSC by FACS. The expression of CXCR3 and CCR7 was
significantly higher on BALB/c-MSC in comparison to NOD-MSC (Fig. 6T). Interestingly,
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CXCR3 has in particular been associated with the migration of autoreactive T cells into the
PLN in the presence of high gradients of IP-10 (CXCL-10) in the PLN (39).
Prevention of diabetes by MSC isolated from NOR mice
It could be argued that the preventive effect we observed in the case of BALB/c-MSC was
due to the activation of immune responses by allogeneic cells. To examine the effect of
MSC from a strain more similar to NOD, we isolated MSC from NOR mice. NOR is a
diabetes-resistant strain with ∼90% genomic identity with NOD mice. NOR share, for
instance, the MHC class II molecule of NOD mice, including the diabetogenic H-2g7
complex (40). For this effort, 5 × 105 MSC were injected into prediabetic female NOD mice
(10 wk of age) once a week for 4 wk, a strategy identical with treatments using BALB/c-
and NOD-MSC. As shown in Fig. 7A, delivery of NOR-MSC to prediabetic NOD mice was
able to prevent diabetes. Furthermore, histological analysis of the pancreas harvested from
NOR-MSC-treated mice at 30 wk posttreatment showed preserved islets with substantial
insulin staining and minimal cellular infiltrate (Fig. 7B). Importantly, similar to BALB/c-
MSC treated mice, we did not observe any tumor development in NOR-MSC-treated
recipients.
Discussion
The incidence of T1D continues to climb steadily, making it one of the most challenging
health issues of the 21st century worldwide (41). In addition, the morbidity and mortality
associated with diabetes are constantly rising and are anticipated to remain a problem for
years to come (41, 42). The use of immunosuppressants to reverse or halt diabetes has
received much attention, but the shortfall of monotherapy and serious morbidity from
lifelong immunosuppression has prompted investigators to search for alternative approaches.
Investigators have begun to use MSC much more quickly than other cell-based therapies in a
variety of human diseases. Interestingly, administration of MSC in many of these settings
has offered significant benefits with no major adverse effects. Although MSC plasticity is a
propitious feature of the cell and has been used as a rationale to develop clinical trials
(http://clinicaltrials.gov; see Refs. 17–23), the immunomodulatory effects of MSC have
recently become of interest as well (11, 12, 14, 24).
Our data in this study show that allogeneic MSC are capable of protecting islet mass and of
delaying the onset of disease when injected into prediabetic NOD mice. Administration of
allogeneic BALB/c-MSC also showed promising results in temporarily reversing
hyperglycemia in new-onset diabetic NOD mice. These novel data indicate that MSC could
be a component of an innovative and successful cell-based regimen for T1D treatment on its
own. An important lesson from intervention therapies in T1D is that monotherapy often fails
to provide a durable favorable outcome, particularly for reversal of the disease. In theory,
MSC therapy could allow investigators to use lesser amounts of immunosuppressive agents,
which, as previously noted, have been shown to carry a high degree of toxicity. Although
the hypoimmunogenicity of allogeneic MSC is certainly of value, MSC are reported to be
efficiently recognized by the host immune response and eventually are rejected (43). The
lack of a long-term effect of BALB/ c-MSC may be related to this recognition and
subsequent rejection. Therefore, future studies should focus on understanding the life span
of MSC and the value of repeated administration for a longer period of time. Additional
research is also needed to identify various synergistic immunosuppressive strategies and to
optimize prevention and reversal of established diabetes. Given that this strategy requires the
generation of large numbers of MSC, these studies will certainly represent a considerable
undertaking. Although the use of MSC comprises an exciting therapeutic approach for T1D,
translating our results to the clinic requires greater investigation to provide robust preclinical
data to safely and effectively use MSC as a cell-based therapy for T1D.
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Our data demonstrating the similarity in the ability of BALB/c-and NOD-MSC to suppress
the T cell response in vitro is in accordance with data using MSC from healthy individuals
and from patients with autoimmune diseases such as scleroderma and rheumatoid arthritis in
which comparable suppression of T cell proliferation was achieved in vitro (44). Given the
disparity we observed in the in vivo effects of NOD- and BALB/c-MSC in regulating
diabetes, we further examined MSC from these two strains to explain the outcome
differences noted in our studies. Although as previously stated, both strains of MSC were
able to suppress alloimmune and autoimmune responses, several intrinsic differences were
evident between them. First, an increased growth rate of NOD-MSC as compared with
BALB/c-MSC was observed as well as a resultant production of a proinflammatory or
diabetogenic cytokine profile. Gene arrays confirm the presence of two distinct gene
profiles, with NOD-MSC expressing more proinflammatory genes compared with BALB/c-
MSC. Furthermore, ultrastructural analysis with electron microscopy revealed differences in
intracytoplasmic organelles and pseudopods, which may have an impact on cell-to-cell
interactions as well as on cell trafficking. Interestingly, the expression of PD-L1, a major
regulatory molecule in T1D, was much greater in BALB/c-MSC, which may serve as a
potential mechanism by which BALB/c-MSC exert their suppressive effect on autoreactive
T cells in vivo (45). Following injection of MSC, we did observe an increase in the
percentage of Tregs and Th2 cytokines, both of which have been shown to be protective in
T1D (32, 33, 46, 47). A key feature of MSC is their ability to selectively migrate into sites
of injury. Moreover, it has been shown that diabetogenic T cells are generated in the PLN,
where they are introduced to Ags by DC. The preferential recruitment of BALB/c-MSC to
the lymph node, along with high levels of PD-L1 expression on BALB/c-MSC, supports the
idea that these cells could directly suppress autoreactive T cells in vivo. Our chemokine
expression studies of MSC suggest a preferential expression of specific chemokine receptors
on BALB/c-MSC, which correlates with the postulation that by inhibiting or stimulating
chemokines/receptors, it will be possible to promote the homing of MSC to specific
anatomical sites to achieve the desired therapeutic effects (36). It is known that
immunoregulatory effects of MSC are exerted through different putative mechanisms,
including immune cell interaction, production of soluble factors, and promotion of Treg
generation (14). These mechanisms are most likely not mutually exclusive, and future
studies should examine their relative contributions to the immunomodulatory functions of
MSC. It should be noted that given the plasticity of MSC, transdifferentia-tion of autologous
MSC could occur; however, because NOD-MSC were observed to have no effect in our
prevention studies, the possibility of MSC differentiation into islets for example seems
unlikely. Nevertheless, this requires additional experiments beyond the scope of the present
study.
We observed rapidly growing tumors in mice treated with autologous MSC. Tumors were
detected in the liver and lungs of our injected mice, where a large number of MSC are
retained after i.v. injection. The incidence of tumor formation was higher in the reversal
group, most likely due to the more intense administration regimen of NOD-MSC in the
reversal group compared with the prevention group. Inbred mice such as NOD have been
shown to carry various genetic abnormalities and are prone to developing lymphoid tumors,
therefore it remains to be elucidated whether autologous MSC indeed pose a risk, whether
the observed tumor formation is related to NOD abnormalities, or whether it has any clinical
implication for humans (48). At present, tumor formation following use of autologous MSC
has not been demonstrated to be a major impediment to current clinical trials, although this
has not been studied in the context of T1D. Nevertheless, it is important to impart this
message to any studies aiming to use autologous MSC to treat the disease of interest (49).
The lack of tumor formation in the case of allogeneic BALB/c-MSC could be due to their
recognition by the host immunosurveillance, ensuring that their proliferation is controlled.
Moreover, NOD-MSC were unable to exhibit any effect on the prevention of diabetes. Lack
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of tumor formation using our NOR-MSC, along with a simultaneous effect on suppressing
diabetes, may argue in favor of using MSC from diabetes-resistant siblings. In summary, we
believe our data provide a basis for the development of a cell-based therapy for which MSC
from nondiabetic donors could be isolated and administered to patients for the prevention
and reversal of T1D. Indeed, the translation of this knowledge into clinical practice could
eventually transform the overall strategy we use to treat this disease.
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FIGURE 1.
MSC characterization and differentiation. Although BALB/c-MSC primarily displayed a
fibroblastic pattern, NOD-MSC grew in large aggregates formed by packed, round to oval,
mid-sized to large cells, with only rare spindle fibroblast-like cells (A). Both MSC were
negative for CD34 and immunoreactive for CD44 and CD105 (B–D) (magnification: ×400
for BALB/c-MSC and ×250 for NOD-MSC). Upon examination by electron microscopy,
BALB/c-MSC appeared as large cells with abundant cytoplasm and smooth cell surfaces
with rare microvilli. Nuclei were irregular with predominant central euchromatin and scarce
peripheral heterochromatin (E). NOD-MSC showed scarce cytoplasm but prominent surface
microvilli, with some dilated rough endoplasmic cisternae, mitochondria, and sparse
lysosomes with irregular nuclei, scarce peripheral heterochromatin, and some nucleoli (F).
Sections were examined using a Philips Morgagni electron microscope. To examine their
“stemness,” we tested MSC cultures for their capacity to differentiate into other cell
lineages. MSC from NOD and BALB/c mice were able to differentiate into chondrocytes
(G), osteocytes (H), and adipocytes (I), shown using ×400 magnification.
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FIGURE 2.
Assessment of MSC for stem cell and immunomodulatory markers by FACS. Stem cell
markers, costimulatory molecules, and apoptotic factors were evaluated in MSC at P4 by
FACS analysis (n = 3 experiments). The stem cell markers CD29 (A), CD44 (B), CD73 (D),
CD105 (F), CD166 (G), and Sca-1 (H) were positive in NOD- and BALB/c-MSC, with
CD105 expression higher in BALB/c-MSC compared with NOD-MSC (p = 0.001). Myeloid
markers such as CD45 (C) and CD90.2 (E) were negative in both strains of MSC. Most
positive costimulatory molecules appeared to be negative or were expressed at very low
levels in both strains (I–L). Among negative costimulatory molecules, PD-1 and PD-L2
were not expressed in either strain of MSC (M and O), while PD-L1 was more expressed in
BALB/c-MSC compared with NOD-MSC (p = 0.01) (N). FasL was negative in both NOD-
and BALB/c-MSC (Q ), but Fas was expressed by both strains (P). MSC were also
challenged for 48 h with IL-1β. In BALB/c-MSC, but not in NOD-MSC, the expression of
PD-L1 increased (BALB/c-MSC vs NOD-MSC, p = 0.024) (R).
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FIGURE 3.
Cytokine profile of BALB/c- vs NOD-MSC and their ability to suppress allogeneic and au-
toantigen-specific T cell proliferation. A, NOD-MSC produced higher levels of
proinflammatory cytokines/ chemokines including IL-1α (p = 0.01), IL-1β (p= 0.04), IP-10
(p = 0.003), and MCP-1 (p = 0.007) (mean of duplicate wells/experiment, four experiments).
B, Both BALB/c- and NOD-MSC were found to inhibit the MLR response compared with
control (p< 0.001), although BALB/c-MSC were more potent in their ability to abrogate
allogeneic T cell proliferation (p< 0.001 compared with NOD-MSC). C, BALB/c- and
NOD-MSC similarly inhibited the proliferation of autoreactive T cells extracted from
transgenic BDC2.5 mice in response to autoantigen by CFSE dilution (p = 0.04) (as
calculated by proliferation index, mean of triplicate wells, representative of two
experiments).
Fiorina et al. Page 16
J Immunol. Author manuscript; available in PMC 2014 January 19.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
FIGURE 4.
Prevention of diabetes by BALB/c-MSC in NOD mice. BALB/c-MSC or NOD-MSC (5 ×
105) were injected i.v. once a week for 4 wk into prediabetic 10-wk-old NOD mice (n = 35
mice for BALB/c-MSC, n = 28 mice for NOD-MSC, n = 3 experiments). A, BALB/c-MSC
(p = 0.04 compared with controls), but not NOD-MSC, significantly delayed the onset of
T1D in 37% of treated NOD mice in the long-term (up to 40 wk of age). B, At 22 wk of age,
pancreata from normoglycemic BALB/c-MSC-treated mice showed a scanty infiltrate
compared with NOD-MSC-treated and untreated controls (1, 2, and 3, respectively) with
very few CD3+(4–6) and B220+ cells (10–12), which conversely infiltrated the islets of
NOD-MSC-treated and untreated controls. 7–9, Very few FoxP3+ cells were detected within
the islets of all three groups of mice. Insulin (13–15) and glucagon (16–18) staining showed
well-preserved islets, particularly in the BALB/c-MSC-treated mice, whereas a loss of
insulin staining and islet morphology was evident in NOD-MSC-treated or untreated mice.
C, At 22 wk of age, BALB/c-MSC-treated NOD mice showed a lower insulitis score than
age-matched normoglycemic NOD-MSC-treated or untreated control mice, and BALB/c-
MSC-treated mice showed a similar pattern of insulitis as untreated 10-wk-old
normoglycemic NOD mice. Insulitis was scored by counting at least 50 islets/mouse from at
least three mice/group. Photomicrographs were taken on an Olympus BX41 microscope at
indicated magnifications using an Olympus Q-color5 digital camera and analyzed with
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Adobe Photoshop Elements 2.0. All photos were taken at ×400 original magnification. D,
Assessment of Th1 vs Th2 cytokine shift. Splenocytes of normoglycemic BALB/c- or NOD-
MSC-treated and normoglycemic untreated control mice were isolated at 14 wk of age and
were challenged with the BDC2.5 peptide in an ELISPOT assay to evaluate cytokine
production. A reduction in IFN-γ production was evident for BALB/c-MSC- (p = 0.01) and
NOD-MSC-treated mice (p = 0.005). The production of Th2 cytokines (IL-4 [p< 0.0001]
and IL-10 [p = 0.01]) was higher in BALB/c-MSC-treated mice (but not in NOD-MSC-
treated) compared with controls.
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FIGURE 5.
Temporary reversal of diabetes in NOD mice by BALB/c-MSC. The effect of BALB/c- and
NOD-MSC on reversing hyperglycemia in new-onset hyperglycemic NOD mice was
determined. After the second consecutive hyperglycemic measurement (>250 mg/dl) within
24 h, NOD mice were injected i.v. with 1 × 106 allogeneic BALB/c-MSC or syngeneic
NOD-MSC twice a week for 4 wk. Seven of eight BALB/c-MSC-treated mice remained
normoglycemic for an average of 41.5 days as compared with 22.5 days for control (p =
0.0002), whereas NOD-MSC conferred no protection (A–C). In the BALB/c-MSC-treated
mice 14 days after treatment, islets showed very mild infiltrate confined to the borders of β
cells with an almost complete absence of B220+ and CD3+ cells (E) compared with the
untreated control, which showed a considerable number of B220+ and CD3+ infiltrating
cells (D). F, Ninety days after the onset of hyperglycemia, islets from BALB/c-MSC-treated
mouse appeared extensively infiltrated with preserved islet structure.
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FIGURE 6.
Neoplasia in NOD-MSC-treated mice. The tumor detected in NOD-MSC-treated mice
formed nodular masses of 1.5 cm in diameter in the legs of mice, and the tail was completely
involved by nodular masses (A). Tumors were also identified in the lung and liver as
numerous nodules 0.1–0.3 cm in diameter (B and C). Optical microscopy showed that the
malignant tumor was formed of a homogeneous population of malignant spindle cells in
sheets and fascicles (400×) (D). The tumor invaded muscle, nerve, and annexal structures of
the skin and bone (E). The tumor also was shown to invade the peritoneum and was located
adjacent to the colon (F). In the lung, the tumors formed nodular masses with alveolar wall
infiltration (G) and the tumors in the liver appear as nodular masses (H) (×200). Electron
microscopy of the hepatic tumor identified compact, intertwined processes covered by basal
lamina, consistent with Schwann cell differentiation (I) (×19,000). The diagnosis was
suggestive of a malignant peripheral nerve sheath tumor. Hierarchical cluster analysis of
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differentially expressed genes in NOD- and BALB/c-MSC. Each row represents a single
gene (identified by its abbreviation to the right; please refer to Tables I and II for
corresponding gene nomenclature). Each column represents the average of four replicates/
experiment. Color blocks represent significantly regulated genes (red blocks indicate
overexpressed genes and blue blocks indicate underexpressed genes). Color codes at the
bottom correlate color intensity with -fold regulation. Analysis of the gene expression
profile of NOD- and BALB/c-MSC (obtained from normoglycemic NOD mice and age-
matched BALB/c mice) demonstrated that a number of genes, notably several promoting
cell cycle and proliferation, were up-regulated in NOD-MSC (sample nos. 5 to 8) vs BALB/
c-MSC (sample nos. 1 to 4) (J). For a list of genes, please refer to data Tables I and II.
Monitoring the trafficking of BALB/c- and NOD-MSC in NOD mice. CFSE-labeled BALB/
c- and NOD-MSC were injected into 10-wk-old NOD mice, and at day 3 lymphoid organs
and pancreata were examined for the presence of MSC. Spleen (K), pancreas (N), and PLN
(Q) from non-injected mice were used as negative controls. MSC distribution was similar in
both spleen and pancreas of BALB/c-MSC-treated (L and O, respectively) and NOD-MSC-
treated mice (M and P, respectively). However, a greater number of BALB/c-MSC (average
of 20 cells) was observed in the PLN of NOD mice (R) as compared with NOD-MSC-
treated animals (two cells) (S). Cells were counterstained for 2 min with 300 nM 4’,6-
diamidino-2-phenylindole (DAPI) to distinguish nucleated cells. Adjacent sections were
collected at a distance of 100 µm. Photographs were taken using a Nikon E-1000
epifluorescence microscope, with a ×40 objective (×400 total magnification). Asterisks
indicate CFSE-labeled MSC; CFSE-labeled MSC appear bright green; blue indicates DAPI
nuclear counterstaining. Assessment of chemokine receptor expression in MSC by FACS.
The expression of CXCR3 and CCR7 was significantly higher in BALB/c-MSC as
compared with NOD-MSC (p = 0.04 and p = 0.01, respectively, data representative of three
experiments) (T).
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FIGURE 7.
The effect of NOR-MSC in preventing diabetes in NOD mice. NOR-MSC (5 × 105) were
injected i.v. into prediabetic female 10-wk-old NOD mice once a week for 4 wk. NOR-MSC
were generated from female NOR mice (≤10 wk of age). Occurrence of hyperglycemia was
monitored beginning 1 wk after the first injection of MSC and was used to evaluate diabetes
development. Compared with untreated NOD, the onset of diabetes was significantly
delayed in NOD mice treated with NOR-MSC (A). At 30 wk posttreatment, pancre-ata were
harvested from NOD mice treated with NOR-MSC. Islet structure was found to be intact
with preserved insulin and glucagon staining and little cellular infiltrate (B). All photos were
taken at 400× original magnification.
Fiorina et al. Page 22
J Immunol. Author manuscript; available in PMC 2014 January 19.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Fiorina et al. Page 23
Table I
Down-regulated genes in NOD-MSC compared with BALB/c-MSC
Symbol Name Function
Whdc1 WAS protein Not specified
H2-Ab1 Histocompatibility Ag processing and presentation
Sort1 SORTILIN, SORT1 Cell differentiation
Zfp612 Zinc finger protein 612 Regulation of transcription, DNA-dependent
Aldh1a1 Aldehyde dehydrogenase family Morphogenesis
Metabolic process
Oxidation reduction
Positive regulation of apoptosis
Retinoic acid metabolic process
Amy1 Amylase 1 Carbohydrate metabolic process
Amy2 Pancreatic amylase 2 Carbohydrate metabolic process
E030049G20Rik E030049G20Rik Not specified
E230025E14Rik Erythrocyte protein band Mesoderm development
Itga8 Integrin α 8 Cell adhesion and differentiation and matrix
  organization and biogenesis
Positive regulation of TGFβ signaling
  pathway
Aass Aminoadipate-semialdehyde synthase Generation of precursor metabolites and energy
Bst2 Bone marrow stromal cell Ag 2 Not specified
Hig1 HIG1 domain family Response to stress
Pla1a Phospholipase A1 Lipid catabolic process
Abat 4-aminobutyrate aminotransferase Neurotransmitter catabolic process
1700027N10Rik RIKEN cDNA 1700027N10 gene Not specified
Mlana Melanoma-associated Ag Not specified
Sytl4 Synaptotagmin-like 4 Intracellular protein transport
Pou3f4 POU domain, class 3, transcription
  factor 4
Morphogenesis
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Table II
Up-regulated genes in NOD-MSC compared with BALB/c-MSC
Symbol Name Function
Plf Prolactin family Positive regulation of neuroblast proliferation
Plf2 Prolactin family 2 Positive regulation of cell proliferation
Hist1h2ah Histone cluster Nucleosome assembly
Mrpplf3 Mitogen regulated protein Biological process
2310037P21Rik Transmembrane protein 158 Not specified
Mela Melanoma antigen DNA recombination
Tk1 Thymidine kinase 1 DNA replication
2610019I03Rik Centromere protein M proliferation-associated
  nuclear element 1
Not specified
Mcm6 Mini-chromosome maintenance-deficient 6 DNA replication
Birc5 Baculoviral IAP repeat-containing 5 Anti-apoptosis
Cyp51 Cytochrome P450 Cholesterol biosynthetic process
Igfbp3 Insulin-like growth factor-binding protein 3 Regulation of cell growth
2410129E14Rik Tubulin Microtubule-based movement
Col15a1 Collagen, type XV, α 1 Cell adhesion
Gfra1 Glial cell line derived neurotrophic factor
  family receptor α 1
Nervous system development
Tyrosine kinase signaling pathway
Kcnk2 Potassium channel, subfamily K, member 2 G-protein-coupled receptor protein-signaling
  pathway
Psmc1 Protease (prosome, macropain) 26S subunit Protein catabolic process
Ngef Neuronal guanine nucleotide exchange factor Neural cell development and differentiation
Sgol2 Shugoshin-like 2 Cell cycle
Crabp2 Cellular retinoic acid binding protein II Embryonic forelimb morphogenesis
Btc Epidermal growth factor family member Cell proliferation
Eps8 Epidermal growth factor receptor pathway
  substrate 8
Proteolysis
Mcf2l Mcf.2 transforming sequence-like Regulation of Rho protein signal transduction
Pcolce2 Procollagen C-endopeptidase enhancer 2 Not specified
Ccnb1 Cyclin B1 Cell cycle
1700022C02Rik Centromere protein P Not specified
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